Arcus Biosciences, Inc. (RCUS) Q3 2020 Earnings Results

Arcus Biosciences Misses on EPS, Stock Down 4.17%

The earnings report indicates that Arcus Biosciences struggled to meet expectations, particularly with its EPS. The stock reacted negatively, dropping 4.17%, likely due to the significant EPS miss and lack of revenue information. Investors may be cautious moving forward without clear guidance from management.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.03	N/A	-91.35%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions impacting performance. They did not provide any updates on future guidance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company acknowledged challenges in meeting market expectations.

Arcus Biosciences Misses on EPS, Stock Down 4.17%

Key numbers

Management commentary

Arcus Biosciences, Inc.

More earnings this week

Arcus Biosciences Misses on EPS, Stock Down 4.17%

Key numbers

Management commentary